Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study

被引:417
作者
Fava, M
Rush, AJ
Trivedi, MH
Nierenberg, AA
Thase, ME
Sackeim, HA
Quitkin, FM
Wisniewski, S
Lavori, PW
Rosenbaum, JF
Kupfer, DJ
机构
[1] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA
[2] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA
[3] Univ Pittsburgh, Ctr Med, Grad Sch Publ Hlth, Dept Psychiat, Pittsburgh, PA USA
[4] Univ Pittsburgh, Ctr Med, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA
[5] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA
[6] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA USA
[7] Dept Vet Affairs Cooperat Studies Program, Palo Alto, CA USA
[8] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY USA
[9] Columbia Univ Coll Phys & Surg, Dept Radiol, New York, NY USA
[10] New York State Psychiat Inst & Hosp, New York, NY USA
关键词
D O I
10.1016/S0193-953X(02)00107-7
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) attempts to fill in major clinical information gaps and to evaluate the theoretical principles and clinical beliefs that currently guide pharmacotherapy of major depressive disorder. The study is conducted in representative participant groups and settings using clinical management tools that easily can be applied in daily practice. Outcomes include clinical outcomes and health care utilization and cost estimates. Research findings should be immediately applicable to, and easily implemented in, the daily primary and specialty care practices. This article provides the overall rationale for STAR*D and details the rationale for key design, measurement, and analytic features of the study.
引用
收藏
页码:457 / +
页数:39
相关论文
共 157 条
[1]   Predictors of persistent social impairment among recovered depressed outpatients [J].
Agosti, V .
JOURNAL OF AFFECTIVE DISORDERS, 1999, 55 (2-3) :215-219
[2]  
AKISKAL HS, 1981, PSYCHIAT CLIN N AM, V4, P25
[3]   CHANGING CLINICAL-PRACTICE - PROSPECTIVE-STUDY OF THE IMPACT OF CONTINUING MEDICAL-EDUCATION AND QUALITY ASSURANCE PROGRAMS ON USE OF PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
FORCIER, A ;
PATWARDHAN, NA .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (06) :669-677
[4]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[5]  
[Anonymous], 1993, AM J PSYCHIAT, V150, P1
[6]   Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors:: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study [J].
Appelberg, BG ;
Syvälahti, EK ;
Koskinen, TE ;
Mehtonen, OP ;
Muhonen, TT ;
Naukkarinen, HH .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (06) :448-452
[7]   Triiodothyronine augmentation in the treatment of refractory depression - A meta-analysis [J].
Aronson, R ;
Offman, HJ ;
Joffe, RT ;
Naylor, CD .
ARCHIVES OF GENERAL PSYCHIATRY, 1996, 53 (09) :842-848
[8]   COMPLIANCE WITH PHARMACOTHERAPY IN MOOD DISORDERS [J].
BASCO, MR ;
RUSH, AJ .
PSYCHIATRIC ANNALS, 1995, 25 (05) :269-+
[9]   A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation [J].
Baumann, P ;
Nil, R ;
Souche, A ;
Montaldi, S ;
Baettig, D ;
Lambert, S ;
Uehlinger, C ;
Kasas, A ;
Amey, M ;
JonzierPerey, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (04) :307-314
[10]   FLUOXETINE IN TRICYCLIC REFRACTORY MAJOR DEPRESSIVE DISORDER [J].
BEASLEY, CM ;
SAYLER, ME ;
CUNNINGHAM, GE ;
WEISS, AM ;
MASICA, DN .
JOURNAL OF AFFECTIVE DISORDERS, 1990, 20 (03) :193-200